Irish health experts have warned against using products marketed as retatrutide after patients presented to hospitals with severe vomiting and kidney problems. Retatrutide remains an investigational medicine and is not approved for routine public use anywhere in the world.
Health professionals in Ireland have warned the public not to use retatrutide obtained online, through social media or from fitness networks after patients reportedly required hospital treatment for severe side effects.
Retatrutide, sometimes shortened to “reta,” is an experimental injectable medicine being developed by Eli Lilly for obesity and related metabolic conditions. It is still undergoing clinical trials and has not been approved for general human use or sale.
Despite its investigational status, products promoted as retatrutide are being offered through social media accounts, online sellers and some fitness communities. Irish doctors say people have used these injections without medical supervision, sometimes following advice from personal trainers rather than qualified healthcare professionals (1✔ ✔Trusted Source
Public warned not to take unapproved weight-loss drug – RTÉ News
Advertisement
Patients Reported Vomiting and Kidney Problems
Professor Donal O’Shea, the Health Service Executive’s clinical lead for obesity, said hospitals are seeing patients with side effects after using products sold as retatrutide.
He described a patient who had reportedly received injections twice weekly from a personal trainer before being admitted to hospital with vomiting and kidney disease.
Persistent vomiting can become medically dangerous because prolonged fluid loss may cause severe dehydration, electrolyte disturbances and acute kidney injury. Nausea, vomiting, diarrhoea and constipation are among the gastrointestinal effects reported during retatrutide research.
However, products obtained outside legitimate clinical trials create additional uncertainty. Buyers may not know what the injection contains, how concentrated it is or whether it has been manufactured, transported and stored under safe conditions.
One fitness coach told RTÉ News that she became severely unwell shortly after injecting a product sold as retatrutide. She reported repeated vomiting, an inability to eat normally and nearly collapsing in a gym before deciding to stop using it (1✔ ✔Trusted Source
Public warned not to take unapproved weight-loss drug – RTÉ News
Advertisement
Retatrutide Remains an Experimental Medicine
Retatrutide is designed to act on three hormone pathways: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. These pathways influence appetite, blood glucose regulation and energy metabolism.
The medicine has attracted considerable attention because Lilly’s manufacturer-announced Phase 3 results have reported substantial weight loss. In one trial involving adults with obesity or overweight and type 2 diabetes, participants receiving the highest studied dose lost an average of 20.8% of their body weight after 80 weeks.
Another Phase 3 trial involving people with severe obesity and established cardiovascular disease reported average weight loss of up to 22.6% after 80 weeks (1✔ ✔Trusted Source
Public warned not to take unapproved weight-loss drug – RTÉ News
Promising trial results do not mean that retatrutide is ready for unrestricted or unsupervised use. Complete findings require scientific presentation, peer review and regulatory assessment. Regulators must decide whether the benefits outweigh the risks, which patients may receive the medicine and what dosing, warnings and monitoring are required.
Clinical-trial participants also receive a pharmaceutical product manufactured to controlled standards. Their doses are carefully managed, and their health is monitored throughout the study. These safeguards do not apply to products purchased through unofficial sellers.
Advertisement
Online Products May Not Match the Trial Medicine
A substance advertised as retatrutide online may contain an incorrect dose, impurities, contaminants or a different ingredient altogether. Labels such as “research use only” do not mean that a product is safe for human injection.
This distinction is important because social media discussions often present experimental medicines as if they were established weight-loss treatments. Some users may increase their dose or inject more frequently when weight loss slows, increasing the possibility of serious harm.
Eli Lilly has called on social media companies to prevent the promotion and sale of unauthorised retatrutide products. Meta and TikTok say they prohibit content that sells or provides access to unapproved or high-risk weight-loss products.
TikTok has also banned hashtags including #retatrutide and #reta. However, RTÉ News reported that some sellers continue to evade platform restrictions, while Ireland’s Health Products Regulatory Authority has observed an upward trend in social media pages illegally selling weight-loss drugs (1✔ ✔Trusted Source
Public warned not to take unapproved weight-loss drug – RTÉ News
Patients Should Tell Doctors What They Injected
Doctors are also concerned that some patients do not initially disclose their use of retatrutide because they feel embarrassed or fear being judged. Without this information, healthcare professionals may struggle to identify the cause of vomiting, abdominal symptoms or kidney problems.
Anyone who becomes unwell after using an unapproved weight-loss injection should tell clinicians exactly what was taken, how much was used, how frequently it was injected and where it was obtained.
Urgent medical attention is particularly important for repeated vomiting, severe abdominal pain, faintness, weakness, reduced urination or an inability to keep fluids down.
Retatrutide’s clinical-trial results may eventually support a new treatment option if regulators determine that it is sufficiently safe and effective.
Until then, the reported benefits cannot be transferred to unverified injections sold online or administered without medical supervision.
References:
- Public warned not to take unapproved weight-loss drug – RTÉ News (https://www.rte.ie/news/ireland/2026/0823/)
Source-Medindia